RxDoctor Payments Data

Meredith Overholt, MD

Dermatology · Knoxville, TNNPI 1801949151

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 78.8% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $7,785 and has fallen 72.3% since, to $2,157 in 2025.

$21,431in general payments, 2019–2025

Across 337 payments — averaging $63.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Merz North America, Inc.$750
  • Galderma Laboratories, L.p.$446
  • Johnson & Johnson$429
  • E.r. Squibb & Sons, L.L.C.$370
  • LEO Pharma Inc.$327
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$1,0005%
  • Speaking & faculty fees$11,82555%
  • Travel & lodging$1,5527%
  • Food & beverage$6,80932%
  • Education$2451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,431 in reported general payments places this provider in the 85th percentile of 209 dermatology providers in Tennessee.

See all dermatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$813,403
Medicare patients
910
Services billed
7,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$62,868
Dupixent SyringeDupilumab13$46,469
Fluorouracil91$6,150
Clobetasol Propionate81$3,529
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet27$868
Fluocinonide20$595
Mupirocin72$552
Triamcinolone Acetonide53$549
Ketoconazole22$464
Doxycycline Hyclate30$403
Doxycycline Monohydrate24$345
Mometasone Furoate21$312
ValacyclovirValacyclovir Hcl22$266
Fluconazole14$152
Hydroxychloroquine Sulfate11$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$165$62,86813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 209 dermatology providers in Tennessee.

Other dermatology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →